|
Dr. Kauffman received his M.D. and Ph.D. (molecular biology and biochemistry) at Johns Hopkins and his postdoctoral training at Harvard University. He is board certified in internal medicine, and comes with over 10 years of extensive experience in drug discovery and development. From September 2002 until August 2006, Dr. Kauffman served as President and Chief Executive Officer of Predix Pharmaceuticals, Inc. Predix Pharmaceuticals Inc. was founded in September 2002 as the wholly-owned U.S. subsidiary of Predix Pharmaceuticals Ltd., an Israeli biopharmaceutical company specializing in G-protein coupled receptor modeling and small molecule drug development. Dr. Kauffman joined Predix after being the Vice President, Medicine, and Proteasome Inhibitor (VELCADE) Program Leader at Millennium Pharmaceuticals Inc. Prior to that, Dr. Kauffman held senior positions at Millennium Predictive Medicine, Inc., as cofounder and Vice President of Medicine, and at Biogen Corporation. He currently serves on the board of directors of Bioenvision, Inc. and CombinatoRx, Inc. both publicly traded biopharmaceutical companies. | 